Nicholas Conrad Smith bought $101k of ANRO
CHIEF FINANCIAL OFFICER at Alto Neuroscience, Inc.. 6,150 shares at an average of $16.36, traded Mar 28, 2024, filed Apr 1, 2024.
Score components
- +22RoleCFO
- +10Trade size$101k at market
- +6Relative to holdingsHoldings up 30%
- +4Price context30% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.6%, 3m -21.7%, 6m -21.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-009533, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 28, 2024 | POpen-market purchase Common Stock | +1,600 | $15.80 | $25k | 22,316 | Apr 1, 2024 |
| Mar 28, 2024 | POpen-market purchase Common Stock | +4,550 | $16.56 | $75k | 26,866 | Apr 1, 2024 |
Related signals
Other insiders at Alto Neuroscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | Alto Neuroscience, Inc. | Nicholas Conrad Smith PRESIDENT AND CFO | $3.6M 134,886 shares | -100% | |
| 45Moderate | ANRObuy Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $191k 15,000 shares | +60% | |
| 60Notable | Alto Neuroscience, Inc. | Alpha Wave Global, LP owner | $9.6M 600,000 shares | +19% | |
| 52Moderate | Alto Neuroscience, Inc. | Amit Etkin PRESIDENT AND CEO | $50k 3,125 shares | +0% | |
| 63Notable | Alto Neuroscience, Inc. | Adam Savitz CHIEF MEDICAL OFFICER | $272k 17,000 shares | +217% | |
| 60Notable | Alto Neuroscience, Inc. | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | $25k 1,563 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.